We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

22 hedge funds and large institutions have $1.76M invested in Titan Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

5% more funds holding

Funds holding: 21 → 22 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

16% less capital invested

Capital invested by funds: $2.1M → $1.76M (-$343K)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
4
Closed
2
Calls
$53K
Puts
–
Net Calls
+$53K
Net Calls Change
-$13K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$75.3K
2
Renaissance Technologies
Renaissance Technologies
New York
+$58.5K
3
Citadel Advisors
Citadel Advisors
Florida
+$41.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$12.5K
5
AG
Advisor Group
Arizona
+$4.18K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$41.8K
2
WS
Wedbush Securities
California
-$18K
3
TSS
Two Sigma Securities
New York
-$16K
4
BlackRock
BlackRock
New York
-$4.18K
5
Morgan Stanley
Morgan Stanley
New York
-$4.18K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$632K +$58.5K +14 +9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$404K +$12.5K +3 +3%
WPA
3
Winning Points Advisors
Florida
$141K – – –
Millennium Management
4
Millennium Management
New York
$95K -$41.8K -10 -29%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$91K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$80K +$75.3K +18 +600%
BlackRock
7
BlackRock
New York
$64K -$4.18K -1 -6%
Northern Trust
8
Northern Trust
Illinois
$55K – – –
Bank of America
9
Bank of America
North Carolina
$39K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$39K +$41.8K +10 New
SRAM
11
Stone Ridge Asset Management
New York
$30K -$4.18K -1 -11%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$29K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$17K +$4.18K +1 +25%
WAM
14
Wealthspire Advisors (Maryland)
Maryland
$12K – – –
CCB
15
Cutter & Co Brokerage
Missouri
$11K – – –
Morgan Stanley
16
Morgan Stanley
New York
$4K -$4.18K -1 -50%
MAM
17
Meeder Asset Management
Ohio
$3K – – –
WIM
18
Westside Investment Management
California
$2.89K – – –
APA
19
American Portfolios Advisors
New York
$2.87K – – –
BCM
20
Blume Capital Management
California
$2K – – –
AG
21
Advisor Group
Arizona
$2K +$4.18K +1 New
UBS Group
22
UBS Group
Switzerland
$2K +$4.18K +1 New
CIBC Private Wealth Group
23
CIBC Private Wealth Group
Georgia
$1K – – –
KF
24
Krilogy Financial
Missouri
$1K – – –
LF
25
Lee Financial
Texas
$1K – – –
1
2

TTNP Hedge Fund Activity: Q1 2018 in Review

22 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2018, worth a combined $1.76M — down 16% from $2.1M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new TTNP positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $75.3K. The largest seller was Millennium Management, cutting an estimated $41.8K.

  • 22 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2018, up from 21 in Q4 2017.
  • Funds reported $1.76M of Titan Pharmaceuticals stock for Q1 2018, down 16% quarter-over-quarter.
  • 3 funds opened new Titan Pharmaceuticals positions in Q1 2018 and 2 closed out, a net change of +1 holder.
  • The largest Titan Pharmaceuticals buyer in Q1 2018 was Susquehanna International Group, an estimated $75.3K added.
  • The largest Titan Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $41.8K sold.

Based on aggregated 13F filings for Q1 2018.